NCT01154634

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.

Detailed description

A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers.

Conditions

• Reflux

Interventions

Type	Name	Description
DRUG	AZD2516, 5 mg	Capsule, oral
DRUG	AZD2516, 16 mg	Capsule, oral
DRUG	AZD2516, 40 mg	Capsule, oral
DRUG	Placebo	Capsule, oral

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2010-07-01
• Last updated: 2012-08-30
• Results posted: 2012-08-13

Locations

2 sites across 2 countries: Belgium, Netherlands